For research use only. Not for therapeutic Use.
GDC-0449 (Vismodegib) is a potent inhibitor of the Hedgehog signaling pathway, targeting the Smoothened (SMO) receptor. It is used in the treatment of advanced basal cell carcinoma (BCC), including those with metastatic or locally advanced disease. By inhibiting the Hedgehog pathway, GDC-0449 prevents the activation of downstream signaling involved in tumor growth. It is also being investigated for use in other malignancies driven by Hedgehog pathway dysregulation, offering a targeted approach for precision cancer therapy.
| Catalog Number | A000583 |
| CAS Number | 879085-55-9 |
| Synonyms | Vismodegib ; GDC-0449 ; |
| Molecular Formula | C₁₉H₁₄Cl₂N₂O₃S |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | >21.1mg/mL in DMSO |
| Storage | -20 ℃ |
| InChI | InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) |
| InChIKey | BPQMGSKTAYIVFO-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl |
